文献速递血液净化与透析慢性肾脏病

COVID-19大流行期间新发终末期肾病患者治疗变化

Changes in Treatment of Patients with Incident ESKD during the Novel Coronavirus Disease 2019 Pandemic.
PubMed 文献 · J Am Soc Nephrol · 2021-09-17

本研究基于美国医保数据,比较2020年上半年与2017-2019年历史趋势,发现2020年新发ESKD发病率显著下降,第15-18周发病率比0.75,75岁以上人群下降更明显;透析启动时eGFR降低,中心静脉导管使用增加。

要点

  • 2020年第15-18周新发ESKD发病率比0.75,75岁以上人群IRR 0.69。
  • 第19-22周透析启动时eGFR平均下降0.33 ml/min/1.73m2。
  • 中心静脉导管启动透析的比值比1.30,绝对增加3.3%。

核心结论

  • COVID-19第一波期间新发ESKD治疗人数降至2011年以来未观察到的水平。
  • ESKD相关护理的变化可能反映大流行早期医疗可及性差异。

研究设计与样本

  • 使用美国Centers for Medicare and Medicaid Services数据,比较2020年上半年与2017-2019年历史趋势。
  • 采用Poisson回归分析发病率,logistic回归分析二分类结局。

主要发现

  • 2020年第15-18周(4月)新发ESKD发病率比0.75(95%CI 0.73-0.78)。
  • 75岁及以上人群发病率比0.69(95%CI 0.66-0.73)。
  • 第15-18周抢先肾移植发病率比0.56(95%CI 0.46-0.67)。
  • 第19-22周透析启动时平均eGFR下降0.33 ml/min/1.73m2,非西班牙裔黑人患者下降0.61 ml/min/1.73m2。
  • 第19-22周以eGFR<10 ml/min/1.73m2启动透析的比值比1.14(95%CI 1.05-1.17),绝对增加2.9%。

关键数值与推荐

  • 第11-14周启动腹膜透析(vs血液透析)的比值比1.24(95%CI 1.14-1.34),绝对增加2.3%。
  • 中心静脉导管启动透析的比值比1.30(95%CI 1.20-1.41),绝对增加3.3%。

临床怎么用

  • 疫情期间需关注新发ESKD患者就医延迟及透析启动时肾功能更差的情况。
  • 应警惕中心静脉导管使用增加带来的感染风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The COVID-19 pandemic caused major disruptions to care for patients with advanced CKD. METHODS: We investigated the incidence of documented ESKD, ESKD treatment modalities, changes in eGFR at dialysis initiation, and use of incident central venous catheters (CVCs) by epidemiologic week during the first half of 2020 compared with 2017-2019 historical trends, using Centers for Medicare and Medicaid Services data. We used Poisson and logistic regression for analyses of incidence and binary outcomes, respectively. RESULTS: Incidence of documented ESKD dropped dramatically in 2020 compared with the expected incidence, particularly during epidemiologic weeks 15-18 (April, incidence rate ratio [IRR], 0.75; 95% CI, 0.73 to 0.78). The decrease was most pronounced for individuals aged ≥75 years (IRR, 0.69; 95% CI, 0.66 to 0.73). Pre-emptive kidney transplantation decreased markedly during weeks 15-18 (IRR, 0.56; 95% CI, 0.46 to 0.67). Mean eGFR at dialysis initiation decreased by 0.33 ml/min per 1.73 m2 in weeks 19-22; non-Hispanic Black patients exhibited the largest decrease, at 0.61 ml/min per 1.73 m2. The odds of initiating dialysis with eGFR <10 ml/min per 1.73 m2 were highest during weeks 19-22 (May, OR, 1.14; 95% CI, 1.05 to 1.17), corresponding to an absolute increase of 2.9%. The odds of initiating peritoneal dialysis (versus hemodialysis) were 24% higher (OR, 1.24; 95% CI, 1.14 to 1.34) in weeks 11-14, an absolute increase of 2.3%. Initiation with a CVC increased by 3.3% (OR, 1.30; 95% CI, 1.20 to 1.41). CONCLUSIONS: During the first wave of the COVID-19 pandemic, the number of patients starting treatment for ESKD fell to a level not observed since 2011. Changes in documented ESKD incidence and other aspects of ESKD-related care may reflect differential access to care early in the pandemic.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Wetmore JB, Johansen KL, Liu J, et al. Changes in Treatment of Patients with Incident ESKD during the Novel Coronavirus Disease 2019 Pandemic. J Am Soc Nephrol. 2021. PMID: 34535558. doi:10.1681/ASN.2021040579

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。